Public interest group accuses FDA of trying to discredit whistleblower

doi:10.1136/bmj.329.7477.1255-a

BMJ 2004;329:1255 (27 November), doi:10.1136/bmj.329.7477.1255-a

News

Public interest group accuses FDA of trying to discredit whistleblower

Jeanne Lenzer

New York

The first 150 words of the full text of this article appear below.

A public interest group that aims to protect whistleblowersclaimed last week that an attempt had been made by a memberof staff at the Food and Drug Administration to discredit DrDavid Graham, the FDA executive who testified to the US Senatecommittee on 18 November.

Dr Graham, associate director in the FDA's Office of Drug Safety,had carried out a study with Kaiser Permanente of northern Californiathat looked at the cardiovascular risks in patients taking rofecoxib(Vioxx). He had submitted the results of the study to the Lancet.Dr Graham withdrew the study, however, after getting a warningfrom his supervisor.

The FDA issued a statement after the Senate hearing last week,claiming that Dr Graham had failed to adhere to agency protocolwhen he submitted his data to the Lancet.

When the BMJ inquired about the FDA's statement and the possiblepublication of the rofecoxib . . . [Full text of this article]

Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

Relevant Article

Is drug regulation failing?: Kamran Abbasi
BMJ 2004 329: 0. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

(2005). Hit parade. BMJ 330: 485-485 [Full text]
Spiers, A. S D (2005). Save the FDA. BMJ 330: 308-308 [Full text]
Lenzer, J. (2004). Crisis deepens at the US Food and Drug Administration. BMJ 329: 1308-1308 [Full text]